William Blair analyst John Boyle initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Outperform rating.The analyst comments "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage